- Home
- GIFT vs ENLV Comparison
GIFT vs ENLV Comparison
Compare GIFT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIFT | ENLV |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 26.6M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | GIFT | ENLV |
|---|---|---|
| Price | $1.06 | $0.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | 28.4K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,142,442.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $0.74 |
| 52 Week High | $2.38 | $2.10 |
Technical Indicators
Market Signals| Indicator | GIFT | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 31.59 |
| Support Level | $0.97 | $0.80 |
| Resistance Level | $1.18 | $0.88 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 35.44 | 6.04 |
Price Performance
Historical ComparisonAbout GIFT RDE Inc.
Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.